



## JS-K and PABA/NO as Antitumor Agents




**TEDCO/NIH/NCI Technology Showcase**

**Larry Keefer, NCI**

*September 25, 2007*




### *JS-K Slows Multiple Myeloma Xenograft Growth...*




Kiziltepe et al., Blood 2007, 110, 709-718.

*...and Greatly Prolongs Survival.*



Kiziltepe et al., Blood 2007, 110, 709-718.

*JS-K Slows Leukemia Xenograft Growth....*




Shami et al., Mol Cancer Ther 2003, 2, 409-417.


*....and Induces Major Tumor Necrosis  
in Vivo.*



**Control  
HL-60**



**JS-K  
HL-60**




Shami et al., Mol Cancer Ther 2003, 2, 409-417.

*JS-K Is Also Active in Vivo Against:*



- Human prostate cancer xenografts;  
Shami et al., Mol Cancer Ther 2003, 2, 409-417.
- Orthotopic rat liver cancer.  
Shami et al., J Med Chem 2006, 49, 4356-4366.

*PABA/NO Slows Ovarian Cancer  
Xenograft Growth Comparably to Cisplatin*



Findlay et al., Mol Pharmacol 2004, 65, 1070-1079.

*For further information*



- Tech transfer (CDAs, CRADAs):  
Dr. Nadezda Radoja, [radojan@mail.nih.gov](mailto:radojan@mail.nih.gov), 301-846-5222
- Licensing:  
Dr. Norbert Pontzer, [PontzerN@OD.NIH.GOV](mailto:PontzerN@OD.NIH.GOV), 301-435-5502
- Biology:  
Dr. Paul Shami, [p.shami@m.cc.utah.edu](mailto:p.shami@m.cc.utah.edu), 801-585-5136
- Chemistry:  
Dr. Larry Keefer, [keefer@ncicrf.gov](mailto:keefer@ncicrf.gov), 301-846-1467